The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioventix Share News (BVXP)

Share Price Information for Bioventix (BVXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,375.00
Bid: 4,300.00
Ask: 4,450.00
Change: 0.00 (0.00%)
Spread: 150.00 (3.488%)
Open: 4,375.00
High: 4,375.00
Low: 4,375.00
Prev. Close: 4,375.00
BVXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Belvoir ups yearly payout; SigmaRoc swings to profit

Mon, 27th Mar 2023 15:01

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday not separately reported by Alliance News.

---------

Belvoir Group PLC - Lincolnshire, England-based property franchise and financial services - Posts revenue of GBP33.7 million for 2022, up 14% from GBP29.6 million in 2021. Revenue from the financial services division increases by 26% to GBP18.1 million, from GBP14.4 million a year earlier. Pretax profit drops slightly to GBP9.1 million from GBP9.3 million, as administrative costs rise by 16% to GBP11.2 million from GBP9.7 million a year earlier. Declares a final dividend of 5.0 pence per share, up 11% from 4.5p a year earlier. This takes the total dividend for 2022 to 9.0p per share, up 5.9% from 8.5p a year prior. Looking ahead, says remains confident that it will perform well against the market in 2023 and beyond.

----------

SigmaRoc PLC - quarried materials company - Says revenue for 2022 is GBP538.0 million, up 98% from GBP272.0 million in 2021. Swings to a pretax profit of GBP42.7 million from a loss of GBP2.3 million, as profit from operations surges to GBP115.9 million from GBP61.9 million a year earlier. Earnings before interest, tax, depreciation and amortisation amount to GBP101.7 million, up from GBP49.3 million in 2021. Earnings per share total 8.0 pence per share, up from 5.4p in 2021. Chief Executive Officer Max Vermorken says the group has delivered performance well ahead of expectations in 2022, and that the start of 2023 has been encouraging.

----------

Plexus Holdings PLC - West Sussex-based engineering services provider - For the six months ended on December 31, sales revenue is GBP709,000, down from GBP734,000 a year before. Pretax loss widens to GBP2.1 million from GBP1.9 million, as administrative expenses increase to GBP2.6 million from GBP2.5 million in 2021. Says the loss comes after absorbing depreciation and amortisation costs of about GBP800,000. Chief Executive Ben van Bilderbeek says: "While the first half of this financial year continued to be challenging with low sales revenue and trading losses, I am encouraged by a number of positive internal and external indicators and developments." Looking ahead, Plexus warns of headwinds in Europe and UK, but says that the global wellhead equipment market is now beginning to thrive, which it says can be positive for the firm.

----------

Northamber PLC - London-based distributor of audio-visual and information technology equipment - Posts revenue of GBP33.6 million for the six months ended on December 31, up 4.1% from GBP32.3 million a year before. However, pretax loss widens to GBP250,000 from GBP116,000, as administrative costs increase to GBP1.8 million from GBP1.6 million a year earlier. Declares an interim dividend of 0.3 pence per share. Looking ahead, Northamber says it remains cautiously optimistic that the investments it has made in supporting its partners will "continue to drive growth of strategic business units although some of these investments returns have been hampered by the impact of inflationary issues".

----------

Bioventix PLC - London-based biotechnology company - Says revenue for 2022 increases by 25% to GBP5.9 million from GBP4.7 million in 2021. Says sales of physical product have performed well, and revenue from its vitamin D antibody and other core antibodies have all increased as anticipated. Pretax profit climbs by 27% to GBP4.5 million from GBP3.6 million, as operating profit grows to GBP4.5 million from GBP3.6 million a year earlier. Declares interim dividend of 62 pence per share, up 20% from 52p a year prior. Looking ahead, says it remains optimistic about its troponin revenue and looks forward to reporting further progress in the second half of the year.

---------

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
29 Mar 2022 17:05

TRADING UPDATES: Solid 2021 for Ten Entertainment, Central Asia Metals

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2022 11:48

Bioventix hikes interim dividend after revenue falls

(Sharecast News) - Monoclonal antibody developer and supplier Bioventix reported an 8% fall in revenue in its first half on Monday, to £4.7m.

Read more
2 Dec 2021 16:04

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
19 Oct 2021 06:54

IN BRIEF: Bioventix lifts payout as revenue rises, but profit slips

IN BRIEF: Bioventix lifts payout as revenue rises, but profit slips

Read more
30 Mar 2021 06:58

IN BRIEF: Bioventix reports first-half fall in profit, raises dividend

IN BRIEF: Bioventix reports first-half fall in profit, raises dividend

Read more
29 Mar 2021 08:58

Bioventix revenue rises in tougher first half

(Sharecast News) - Diagnostic antibody developer Bioventix reported a 1.3% improvement in revenue in its first half on Monday, to £5.2m.

Read more
3 Dec 2020 16:13

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 Oct 2020 14:08

IN BRIEF: Bioventix Hikes Dividend Payout As Annual Earnings Rise

IN BRIEF: Bioventix Hikes Dividend Payout As Annual Earnings Rise

Read more
1 Jul 2020 18:18

UK EXECUTIVE CHANGE SUMMARY: New CFOs At Ideagen And Bioventix

UK EXECUTIVE CHANGE SUMMARY: New CFOs At Ideagen And Bioventix

Read more
1 Jul 2020 09:40

Bioventix appoints Bruce Hiscox as chief financial officer

(Sharecast News) - Antibodies developer Bioventix named Bruce Hiscock would join the group its new chief financial officer on Wednesday.

Read more
31 Mar 2020 18:59

CORRECT: Bioventix Reports "Strong" Interims, Increases Dividend

CORRECT: Bioventix Reports "Strong" Interims, Increases Dividend

Read more
30 Mar 2020 14:19

Bioventix Reports "Strong" Interim Performance, Increases Dividend

Bioventix Reports "Strong" Interim Performance, Increases Dividend

Read more
28 Oct 2019 18:50

DIRECTOR DEALINGS: Bioventix Non-Exec Chair Sells GBP78,000 In Shares

DIRECTOR DEALINGS: Bioventix Non-Exec Chair Sells GBP78,000 In Shares

Read more
21 Oct 2019 11:33

Bioventix full-year revenue and profits improve

(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.

Read more
29 Mar 2019 08:31

Vitamin D antibodies drive first-half growth at Bioventix

(Sharecast News) - Monoclonal antibodies developer and supplier Bioventix reported a 24% improvement in its normalised revenue in its half-year report on Friday, to £4.4m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.